PCT Patents in Blood Anticlot Technology, Medications and
Medical Devices

Thank you for visiting FormulaScan . Please click on the WO Patent No to study the full patent document

PCT - WORLD PATENTS IN BLOOD ANTICLOT DRUGS AND DEVICES PUBLISHED IN 2010


Title: METHODS OF ASSESSING ACTIVITY OF A POLYSACCHARIDE COMPOSITION

Publication No: WO2010/121196
Pub. Date - Int. Class - Applicant: - 21.10.2010 - G01N 33/574 - MOMENTA PHARMACEUTICALS, INC.
Methods of assessing polysaccharide preparations lacking substantial anticoagulant activity are provided herein.


Title: METHOD AND APPARATUS FOR DETECTING PHARMACEUTICALS IN A SAMPLE

Publication No: WO2010/117320
Pub. Date - Int. Class - Applicant: - 14.10.2010 - G01N 21/64 - NICHOLLS, Ian A.
A method and apparatus for measuring a vitamin K antagonizing anticoagulant present in a sample (116), arranged to: irradiate (304) the sample (116) with light from a light source (114) for exciting the anticoagulant through its absorption of the light, the excitation of the sample (116) resulting in a fluorescent emission from the sample (116); measure (306) the fluorescent emission from the sample (116); determine (308) a fluorescence lifetime (T1) of the fluorescent emission of the sample (116); determine (310) an intensity (A1) of the fluorescent emission at the fluorescence lifetime (T1); and determine (312) a amount (c) of the anticoagulant, as a function of the intensity (A1) of the fluorescent emission at the fluorescence lifetime (...


Title: A MULTIPART FLUID SYSTEM AND A SYSTEM FOR REGIONAL CITRATE ANTICOAGULATION IN AN EXTRACORPOREAL BLOOD CIRCUIT

Publication No: WO2010/112538
Pub. Date - Int. Class - Applicant: - 07.10.2010 - A61K 33/06 - GAMBRO LUNDIA AB
The present invention concerns a multipart fluid system for use in CRRT, wherein the multipart fluid system comprises an anticoagulation fluid and at least one fluid from the group consisting of a dialysis fluid and an infusion fluid. According to the invention the anticoagulation fluid comprises at least 8 mM citrate, and the dialysis fluid and/or infusion fluid comprises 2-8 mM citrate and 1-5 mM total calcium. The present invention further concerns a system for regional citrate anticoagulation in an extracorporeal blood circuit.


Title: METHOD FOR ENHANCING INSULIN MEDIATED UPTAKE OF NUTRIENTS INTO CELLS

Publication No: WO2010/105239
Pub. Date - Int. Class - Applicant: - 16.09.2010 - A61K 33/24 - RUSSELL, Kenneth O.
A method increases the uptake of nutrients into cells of an individual. The method includes eating a meal. The meal includes the nutrients. The method also includes taking a vasodilator, a blood thinner, or any combinations thereof. In addition, the method includes applying chromium. The method further includes exercising for a duration of time.


Title: SYSTEM AND METHOD FOR THE RE-ANTICOAGULATION OF PLATELET RICH PLASMA

Publication No: WO2010/104733
Pub. Date - Int. Class - Applicant: - 16.09.2010 - A61M 1/36 - HAEMONETICS CORPORATION
A method for the re-anticoagulation of platelet rich plasma in a blood apheresis system includes priming the blood apheresis system with anticoagulant, such that a volume of anticoagulant is transferred to a PRP container. The method may then transfer the anticoagulant within the PRP container to a red blood cell container, and collect a volume of platelet rich plasma within the PRP container. The platelet rich plasma may be collected in a plurality of cycles. Between collection cycles, the method may transfer a portion of the volume of anticoagulant from the red blood cell container to the PRP container.


Title: SAND FLY SALIVARY PROTEINS AS NOVEL FACTOR XA INHIBITORS AND METHODS OF USE

Publication No: WO2010/078469
Pub. Date - Int. Class - Applicant: - 08.07.2010 - A61K 38/16 - THE USA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
It has been surprisingly discovered that a sand fly salivary gland polypeptide, or a nucleic acid sequence encoding the polypeptide, can function as an anticoagulant. The present disclosure provides methods of treatment of disorders associated with abnormal coagulation of the blood utilizing compositions that include the sand fly salivary gland polypeptides of the disclosure.


Title: ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS

Publication No: WO2010/056765
Pub. Date - Int. Class - Applicant: - 20.05.2010 - A61K 38/48 - PORTOLA PHARMACEUTICALS, INC.
The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.


Title: METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY

Publication No: WO2010/055023
Pub. Date - Int. Class - Applicant: - 20.05.2010 - A61K 31/4439 - BOEHRINGER INGELHEIM INTERNATIONAL GMBH
A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient a dosage of > 150 mg b.i.d. to 300 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.


Title: METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED EFFICACY OVER CONVENTIONAL WARFARIN THERAPY

Publication No: WO2010/055022
Pub. Date - Int. Class - Applicant: - 20.05.2010 - A61K 31/4439 - BOEHRINGER INGELHEIM INTERNATIONAL GMBH
A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.


Title: METHOD FOR TREATING OR PREVENTING THROMBOSIS USING DABIGATRAN ETEXILATE OR A SALT THEREOF WITH IMPROVED SAFETY PROFILE OVER CONVENTIONAL WARFARIN THERAPY

Publication No: WO2010/055021
Pub. Date - Int. Class - Applicant: - 20.05.2010 - A61P 7/02 - BOEHRINGER INGELHEIM INTERNATIONAL GMBH
A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.


Title: TRANSDERMAL DELIVERY OF OLIGOSACCHARIDES

Publication No: WO2010/029552
Pub. Date - Int. Class - Applicant: - 18.03.2010 - A61F 13/70 - TRANSPHARMA MEDICAL LTD.
The present invention relates to a system for facilitating transdermal delivery of oligosaccharides comprising an apparatus that generates micro-channels in the skin of a subject and a skin patch comprising a pharmaceutical composition comprising as an active agent an oligosaccharide. Particularly, the composition comprises an oligosaccharide of 5-20 monosaccharide units, such as a pentasaccharide, which exerts anticoagulant activity. The system is capable of delivering the oligosaccharides into the blood circulation for treating thromboembolic diseases.


Title: METHODS FOR TREATING BLEEDING DISORDERS

Publication No: WO2010/020423
Pub. Date - Int. Class - Applicant: - 25.02.2010 - A61K 31/727 - BAXTER HEALTHCARE S.A.
A method of factor Xl-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject. A method of factor Xl-dependent blood coagulation enhancement in a subject in need of enhanced blood coagulation comprising: (i) selecting a subject that is not deficient for factor Xl; and (ii) administering a therapeutically effective amount of a composition comprising a non-anticoagulant sulfated polysaccharide (NASP) to the subject, wherein the NASP enhances blood coagulation in a factor Xl-dependent manner. A method of identifying a non-anticoagulant sulfated polysaccharid...


Title: FXA INHIBITORS WITH CYCLIC AMIDOXIME OR CYCLIC AMIDRAZONE AS P4 SUBUNIT, PROCESSES FOR THEIR PREPARATIONS, AND PHARMACEUTICAL COMPOSITIONS AND DERIVATIVES THEREOF

Publication No: WO2010/002115
Pub. Date - Int. Class - Applicant: - 07.01.2010 - C07D 413/12 - LEGOCHEM BIOSCIENCE LTD.
The present invention relates to novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group, pharmaceutically acceptable salts thereof, methods for preparing the same and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone group or the pharmaceutically acceptable salts thereof can be effectively used for the treatment of thromboembolism and tumor as an anticoagulant based on the inhibition of factor Xa..
...or search a US patent No (ex:
7666555) or a US patent
application (ex: 2003123456)
or a World (PCT) No (Ex:
2007666555)
Search for anything. Simply
type the words in the box..
World Patents Published in 2011
World Patents Published from 1980 -2009
WORLD - PCT PATENT DOCUMENTS IN BLOOD ANTICLOT TECHNOLOGY PUBLISHED FROM IN 2010
This list includes World Patent Documents published by PCT. The list was retrieved by searching the claims section of all patent applications. Salient search terms included drugs,
medications, formulation and devices related to blood anticlotting; blood thinners, anticoagulants, protease enzymes, coumadin and thrombin drugs, thrombin inhibitors, heparin, warfarin
and related technologies. The document search strategy of Formula Scan™ includes proprietary direct and proximity data mining algorithms to retrieve highly relevant documents.
Clck to enlarge and view details